Pharma segment becomes increasingly predominant
Since 2014 the company's pharmaceutical segment became increasingly predominant. Currently, pharmaceuticals are responsible for around 55 percent of the company's total sales. The strongest therapeutic areas within Johnson & Johnson's pharmaceutical segment are immunology and oncology. Johnson & Johnson is also active in the field of infectious diseases and vaccines. As of February 2021, the company applied to the FDA (U.S. Food and Drug Administration) for an emergency use authorization for its COVID-19 vaccine. With this particular vaccine, there was a great level of excitement because it requires just one shot and does not need to be stored at ultra-cold temperatures.Most valuable within big pharma
As of 2022, Johnson & Johnson continued to be top ranked among biotech and pharmaceutical companies in the world based on market capitalization. Johnson & Johnson is a diversified healthcare company with some 250 subsidiaries that own well-known brands such as Band-Aid, Neutrogena, Tylenol and Acuvue contact lenses. The company's employment saw a constant growth over the last two decades. At year-end 2022, it reported the highest number of employees so far, reaching nearly 153 thousand.
